SELLAS Life Sciences (SLS) Change in Receivables (2013 - 2022)

SELLAS Life Sciences' (SLS) quarterly Change in Receivables came in at $1.0 million in Q1 2022, up 31.93% on a QoQ basis from $758000.0 in Q2 2015.

SELLAS Life Sciences (SLS) Change in Receivables (2013 - 2022) Analysis & Trends

SELLAS Life Sciences (SLS) has 4 years of Change in Receivables data on file, last reported at $1.0 million in Q1 2022.

On a quarterly basis, Change in Receivables changed N/A year-over-year to $1.0 million in Q1 2022; TTM through Mar 2023 was $979000.0, a 38.16% decrease from a year earlier, with the FY2014 full-year figure at -$1.6 million, down 144.64% from the prior year.
Change in Receivables for Q1 2022 stood at $1.0 million, up from $758000.0 in the prior quarter.
Over the last five years, Change in Receivables for SLS reached as high as $1.0 million in Q1 2022 and fell as low as $1.0 million in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	75.30 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-39.80 Mn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	-1.20 Mn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	SELLAS Life Sciences	1.96 Bn	1.96 Bn	-	-

Download Data